DiagnoCure and Genzyme seal lung cancer test pact
This article was originally published in Clinica
Executive Summary
In a bid to optimise its investigational molecular test for lung cancer, DiagnoCure has licensed from Genzyme worldwide exclusive rights to around 40 genes for potential use in detecting the disease. The genes are intended to supplement those in the original version of DiagnoCure's assay - which uses bronchial aspirate samples - and may also be used to develop new tests that employ other sample types such as blood, sputum, or biopsy materials.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.